← All trials
NCT04956666
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- Nov 7, 2022
- Completion date
- Nov 7, 2022
- First posted
- Jul 9, 2021
- Last posted
- Sep 20, 2021
- Enrollment
- 88
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ServierLead sponsor
- ServierCollaborator
- Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and ImmunologyOverall official - principal investigator
- ServierCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.